Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
0.8611 USD   -2.15%
09/27European ADRs Climb Higher in Tuesday Trading
MT
09/26Mereo BioPharma Says Rubric Capital Management Rejected Offer to Resolve Proxy Contest
MT
09/26Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 48,517712884,0--
Enterprise Value (EV)1 64,517151,084,084,084,0
P/E ratio --51,6x-11,6x-11,6x-7,73x
Yield ------
Capitalization / Revenue --3,52x--3,63x
EV / Revenue --3,52x--3,63x
EV / EBITDA --4 912 706x----
Price to Book ------
Nbr of stocks (in thousands) 19 59267 495108 655108 655--
Reference price (GBP) 2,472,621,180,770,770,77
Announcement Date 06/15/202003/31/202103/31/2022---
1 USD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 --36,5--23,1
EBITDA --36,0----
Operating profit (EBIT)1 -39,5-37,6-20,9-40,8-44,8-51,0
Operating Margin ---57,4%---220%
Pre-Tax Profit (EBT)1 -41,1-16614,2-38,2-39,3-62,8
Net income1 -34,8-16412,7-38,6-39,3-62,8
Net margin --34,9%---271%
EPS2 --0,02-0,07-0,07-0,10
Dividend per Share ------
Announcement Date 06/15/202003/31/202103/31/2022---
1 GBP in Million
2 GBP
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2020 S2 2021 S1 2021 S2 2022 Q1 2022 Q2 2022 S1
Net sales1 -36,5----
EBITDA ------
Operating profit (EBIT) -20,9-0,20-20,7---20,6
Operating Margin --0,56%----
Pre-Tax Profit (EBT) -40,310,93,34---21,0
Net income -39,012,10,64---21,0
Net margin -33,2%----
EPS -0,020,00---0,04
Dividend per Share ------
Announcement Date 03/31/202111/02/202103/31/2022---
1 GBP in Million
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt 16,1-----
Net Cash position -5,5377,5---
Leverage (Debt / EBITDA) -0,15x----
Free Cash Flow -----26,0-57,0
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share ------
Cash Flow per Share ------
Capex1 0,02--2,133,194,53
Capex / Sales -----19,6%
Announcement Date 06/15/202003/31/202103/31/2022---
1 GBP in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 93 562 473
Net sales (GBP) 36 464 000
Net sales (USD) 40 631 581
Number of employees 49
Sales / Employee (GBP) 744 163
Sales / Employee (USD) 829 216
Free-Float 51,6%
Free-Float capitalization (USD) 48 296 501
Avg. Exchange 20 sessions (GBP) 514 655
Avg. Exchange 20 sessions (USD) 573 476
Average Daily Capital Traded 0,55%
EPS & Dividend